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ABSTRACT 
It was previously shown that mice with genetic deletion of the neurotrophic factor 
pleiotrophin (PTN-/-) show enhanced amphetamine neurotoxicity and impair extinction of 
amphetamine conditioned place preference (CPP), suggesting a modulatory role of PTN in 
amphetamine neurotoxicity and reward. We have now studied the effects of amphetamine 
(10 mg/kg, 4 times, every 2h) in the striatum of mice with transgenic PTN overexpression 
(PTN-Tg) in the brain and in wild type (WT) mice. Amphetamine caused an enhanced loss 
of striatal dopaminergic terminals, together with a highly significant aggravation of 
amphetamine-induced increase in the number of GFAP-positive astrocytes, in the striatum 
of PTN-Tg mice compared to WT mice. Given the known contribution of D1 and D2 
dopamine receptors to the neurotoxic effects of amphetamine, we also performed 
quantitative receptor autoradiography of both receptors in the brains of PTN-Tg and WT 
mice. D1 and D2 receptors binding in the striatum and other regions of interest was not 
altered by genotype or treatment. Finally, we found that amphetamine CPP was 
significantly reduced in PTN-Tg mice. The data demonstrate that PTN overexpression in 
the brain blocks the conditioning effects of amphetamine and enhances the characteristic 
striatal dopaminergic denervation caused by this drug. These results indicate for the first 
time deleterious effects of PTN in vivo by mechanisms that are probably independent of 
changes in the expression of D1 and D2 dopamine receptors. The data also suggest that 
PTN-induced neuroinflammation could be involved in the enhanced neurotoxic effects of 
amphetamine in the striatum of PTN-Tg mice. 
Keywords: Pleiotrophin, midkine, astrogliosis, inflammation, methamphetamine, reward. 
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1. INTRODUCTION 
According to the European Monitoring Centre for Drugs and Drug Addiction, it is 
estimated that more than 2% of young people (15–34) used amphetamines in 2010 in 
different European countries including Czech Republic (3.2%), Denmark (3.1%), and the 
United Kingdom (2.3%). Ever in lifetime use of amphetamines among young people in 
those countries varies considerably, with levels of 30–70%. Despite widespread use of 
amphetamine-type stimulants, the long-term medical consequences of these drugs abuse 
and dependence have not been addressed until recently. During the past two decades, 
preclinical studies have demonstrated that this type of psychostimulants damages 
dopaminergic neurons, causing striatal dopaminergic denervation and dopaminergic cell 
death in the substantia nigra among other effects (Moratalla et al., 2015). However, clinical 
correlation was not studied until Callaghan and colleagues (2012) probed a ~77% increased 
risk of Parkinson's disease (PD) in amphetamine-type drug abusers (Callaghan et al., 2012). 
Similarly, a recent report indicates a 3-fold increased risk of PD in these drugs users (Curtin 
et al., 2015). Existence of genetic factors underlying individual vulnerability to the 
rewarding effects of amphetamine and dopaminergic neurotoxicity after consumption of 
this type of psychostimulants is known. Uncovering those genetic factors is not only 
clinically relevant but will also help to develop new therapeutic strategies for substance use 
disorders. 
Pleiotrophin (PTN) is a neurotrophic factor known to play a role in amphetamine-
induced neurotoxicity (Alguacil and Herradon, 2015). A single amphetamine 
administration causes a significant upregulation of PTN mRNA levels in the rat brain (Le 
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Greves, 2005) suggesting that PTN takes part in a modulatory mechanism against the 
effects of amphetamine in the brain. Accordingly, extinction of amphetamine-induced 
conditioned place preference (CPP) is impaired in PTN genetically deficient (PTN-/-) mice 
(Gramage et al., 2010a). Furthermore, a periadolescent amphetamine treatment was found 
to produce transient cognitive deficits only in PTN-/- mice, not in wild type (WT) mice 
(Gramage et al., 2013a). Interestingly, amphetamine-induced neurotoxic effects in the 
nigrostriatal pathway are enhanced in PTN-/- mice compared to WT mice (Gramage et al., 
2010b; Soto-Montenegro et al., 2015). Also, it has to be noted that amphetamine-induced 
increase of GFAP-positive astrocytes, a hallmark of the neuroinflammation induced by this 
type of psychostimulants, was slightly increased in the striatum of PTN-/- mice (Gramage 
et al., 2010a). Overall, the data clearly suggest a modulatory role of PTN on amphetamine 
effects (Herradon and Perez-Garcia, 2014). However, the knockout mouse models, 
although invaluable as screening tools in research, have intrinsic limitations including 
ubiquitous absence of the targeted gene and possible developmentally-related mechanisms 
of compensation. To overcome these limitations, we have now studied the rewarding and 
neurotoxic effects of amphetamine in mice with transgenic neuronal PTN overexpression in 
the brain (PTN-Tg mice). In addition, it is interesting to note that overstimulation of 
dopamine D1 (D1R) and D2 receptors (D2R) significantly contributes to the neurotoxic 
effects of amphetamine (Moratalla et al., 2015). Furthermore, dopamine is a crucial 
transmitter in the neuroimmune network (Kustrimovic et al., 2014) and D2R is identified as 
an important component controlling innate immunity and inflammatory response in central 
nervous system (Shao et al., 2013). To test the possibility that differences in these receptors 
could underlie the different genotypic susceptibility to the neurotoxic and 
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neuroinflammatory effects of amphetamine, we carried out quantitative receptor 
autoradiography of D1, D2 receptors in the brains of PTN-Tg and WT mice. 
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2. EXPERIMENTAL PROCEDURES  
2.1.  Animals 
PTN-Tg mice on a C57BL/6J background were generated by pronuclear injection as 
recently described (Ferrer-Alcón et al., 2012; Vicente-Rodriguez et al., 2014a). The 
acceptor vector used was pTSC-a2 and contained the regulatory regions responsible for 
tissue specific expression of Thy-1 gene, which drives neuron-specific expression of 
transgenes (Aigner et al., 1995; Caroni, 1997). PTN specific overexpression in different 
brain areas, including a 20% increase of PTN protein levels in striatum, was established by 
quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), in situ hybridization, and 
by Western blot (Ferrer-Alcón et al., 2012; Vicente-Rodriguez et al., 2015; 2014b). 
Relevant to the behavioral study presented here, there were no differences in motor activity 
and exploration between both genotypes at baseline (Ferrer-Alcón et al., 2012). 
We used male PTN-Tg and WT animals of 9-10 weeks (20-25 g). Mice were housed 
under controlled environmental conditions (22±1 ºC and a 12-h light/12-h dark cycle) with 
free access to food and water.  
All the animals used in this study were maintained in accordance with European 
Union Laboratory Animal Care Rules (86/609/ECC directive) and the protocols were 
approved by the Animal Research Committee of USP-CEU.  
2.2. Amphetamine treatment. 
PTN-Tg and WT mice received 4 injections (i.p.) of amphetamine (10 mg/kg) or 
saline (control, 10 ml/kg), allowing between injections a 2 hour interval. This regimen of 
administrations of amphetamine was previously used to dissect differences between WT 
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and PTN-/- mice (Gramage et al., 2010a,b) and is known to cause significant damage to 
striatal dopaminergic terminals (Krasnova et al., 2001) and astrocytosis (Krasnova et al., 
2005), a neuroinflammatory hallmark in the striatum that has been suggested to underlie the 
cognitive deficits, depression, and parkinsonism reported in amphetamine-type drugs 
addicts (Krasnova et al., 2016). Four days after the animals received the first administration 
of amphetamine or saline (control), mice were euthanized differently for 
immunohistochemistry and autoradiography studies. 
2.3. Immunohistochemistry studies. 
Mice were transcardially perfused with 4% p-formaldehyde and brains were 
removed and conserved in p-formaldehyde for 24 h and transferred to a 30% sucrose 
solution containing 0.02% sodium azide for storage at 4ºC. The brains were cut at a 
thickness of 30 µm using a vibratome (Leica, Wetzlar, Germany). Immunostaining was 
performed in one slice per 180 µm from bregma 1.54 mm to bregma 0.10 mm.  Striatal 
free-floating sections were processed as previously described (Gramage et al., 2010a,b). In 
order to study astrogliosis or dopaminergic terminals, sections were incubated overnight at 
4ºC with anti-GFAP antibodies (1:1000) (n = 4/group) or anti-TH antibodies (1:1000) (n = 
6-7/group), respectively. Both antibodies were purchased from Millipore (Madrid, Spain). 
The sections were then rinsed in PBS three times for 10 min and incubated for 30 minutes 
with the biotinylated secondary antibodies in PBS at room temperature. The avidin–biotin 
reaction was performed using a Vectastain Elite ABC peroxidase kit following the protocol 
suggested by the manufacturer. The immunoreactivity was visualized using 0.06% 
diaminobenzidine and 0.03% H2O2 diluted in PBS. The sections were mounted on 
gelatin/chrome alume-coated slides, air-dried overnight, dehydrated through graded 
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ethanols, cleared in xylene, and coverslipped with DPX medium. Photomicrographs were 
captured with a digital camera coupled to an optical microscope (DMLS, Leica, Solms, 
Germany).  
Image analysis was performed in the three most central slices of each animal. 
GFAP-positive astrocytes were counted in 325 x 435 µm standardized areas and TH-
immunostaining density was analyzed in 230 ×140 µm areas, both located in the medial 
striatum (Gramage et al., 2010a,b).  
The counting of GFAP-positive cells was accomplished with the help of the 
software Scion Image 4.02 (Scion Corporation, Frederick, MD, USA). As previously 
performed (Gramage et al., 2010b), cell counts were made in standardized areas (325 x 435 
µm) obtaining the mean from three sections per animal. Striatal TH-positive fiber staining 
was assessed by optical density (OD) measurements using Image-Pro Plus software 
(Version 3.0.1; Media Cybernetics, Silver Spring, MD). For each animal, the nonspecific 
background correction in each section was done by subtracting the OD value of the corpus 
callosum from the striatal OD value obtained from the same section. 
 
2.4. D1, D2 dopamine receptor and DAT autoradiography 
Different cohorts of mice (n = 5-6/group) were sacrificed 4 days after the last 
injection of saline or amphetamine. The brains were immediately removed, quickly frozen 
in isopentane (-35ºC) and stored at -80ºC until sectioning. Quantitative autoradiography 
was performed as detailed previously for D1, D2 dopamine receptor binding and DAT 
binding (Bailey et al., 2008) using general procedures of Kitchen et al. (1997). Adjacent 20-
µm brain coronal sections were cut at an interval of 300 µm for the determination of total 
and non-specific binding (NSB) of [
3
H]SCH-23390 (containing 1 µM mianserin), 
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[
3
H]raclopride and [
3H]mazindol (containing 0.3 μM desipramine) to D1R, D2R and DAT, 
respectively. Ligand concentrations were 3-4 x Kd, with all ligands used at a concentration 
of 4 nM. This sub-saturation concentration of radioligand was deliberately chosen in order 
to maximize the detection of binding differences if present. For instance, following this 
rationale we previously showed a clear downregulation of striatal [3H]raclopride (4nM) 
receptors in rats treated with chronic escalating dose “binge” cocaine administration 
paradigm but not following chronic steady dose “binge” cocaine administration (Bailey et 
al., 2008). NSB was defined in the presence of cis-flupentixol (10 µM), sulpiride (10 µM) 
or unlabeled mazindol (10 µM) for [
3
H]SCH-23390, [
3
H]raclopride and [
3
H]mazindol 
binding, respectively. Following incubation binding for a period of 90 min or 60 min at 
room temperature or 45 min at 4ºC for D1R, D2R and DAT, respectively, and washing in 
ice-cold buffer (6 x 1 min for D1R and D2R binding and 2 x 1 min for DAT binding), the 
slides were apposed to MR film (Eastman Kodak Co., Rochester, NY, USA) in X-ray 
cassettes together with a set of tritium standards ([
3H]Microscale™, Amersham, UK) for 6 
weeks. Sections were processed together in a paired protocol. Films were developed using 
50% Kodak D19 developer. Quantitative analysis of brain receptors was performed as 
detailed previously (Kitchen et al., 1997; Lena et al., 2004). Using a MCID image analyser 
(Image Research, Canada), brain structures were identified using the mouse brain atlas of 
Franklin & Paxinos (1997). Brain images were analyzed using left and right hemispheres to 
allow duplication of results. The cortical and olfactory tubercle structures were analyzed by 
sampling five to eight times with a box size 15 × 15 mm
2
 in a box tool. All other regions 
were analyzed by freehand drawing tools.  
2.5.  Conditioned Place Preference (CPP) 
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 A biased apparatus was used as previously described (Vicente-Rodriguez et al., 
2014a). One compartment had black floor and walls, and the other had black floor and 
white walls. The phases of CPP included preconditioning (day 1), conditioning (days 2-4) 
and testing (day 5). During preconditioning, mice were free to explore the two 
compartments for a 30-min period; their behavior was monitored by a videotracking system 
(San Diego, California, USA) to calculate the time spent in each compartment. Mice were 
counterbalanced such that half the animals started in one chamber and half started in the 
other. The compartment with white walls was the non-preferred compartment in a similar 
manner by both genotypes (30 - 40% stay of total time in the preconditioning phase). This 
`biased` apparatus and subject assignment, in which mice are paired with the drug in the 
non-preferred compartment, was previously used to study genotypic differences in 
amphetamine- and cocaine-induced CPP (Gramage et al., 2013b; Gramage et al., 2010b). 
The conditioning phase consisted of double conditioning sessions (Gramage et al., 2013b). 
The first one involved a morning session starting at 8 am. All animals received a single 
injection of saline i.p. (10 ml/kg) and were confined to the initially preferred compartment 
for 30 min. In the evening session, starting at 3 pm, the animals were injected (i.p.) with 3.0 
mg/kg amphetamine (n = 10-15/group), or 10 ml/kg saline (n = 5-7/group) as a 
conditioning control, and confined to the initially non-preferred compartment for 30 min. 
The procedure used in days 3 and 4 was the same but the order of the treatments 
(morning/evening) was changed to avoid the influence of circadian variability. In the 
testing phase, mice received a drug-free, 30-min preference test. The time-spent in the non-
preferred (drug-paired) compartment was calculated in all cases. The increase in the time-
spent in the drug-paired compartment in day 5 compared to day 1 (preference score) was 
considered as indicative of the degree of conditioning induced by amphetamine. 
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2.6. Statistics 
All data were expressed as the mean ± SEM and analyzed using Prism software 
(GraphPad, La Jolla, CA, USA). Data obtained from image analysis of striatal 
immunostaining and autoradiography were analyzed using two-way ANOVA. Relevant 
differences were analyzed pair-wise by post-hoc comparisons with Bonferroni’s post-hoc 
tests, considering genotype (PTN-Tg, WT) and treatment (saline, amphetamine) as 
between-subjects factors. Amphetamine preference scores from CPP were confirmed to 
follow a normal distribution with Kolmogorov-Smirnov, D’Agostino and Pearson Omnibus 
and Shapiro-Wilk normality tests, so they were analyzed using a Student’s t-test. P < 0.05 
was considered as statistically significant.  
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3. RESULTS  
3.1.  Enhanced amphetamine-induced loss of dopaminergic terminals in the striatum of 
PTN-Tg mice. 
Since one of the most relevant consequences of amphetamine administration is the 
loss of dopaminergic terminals in the striatum (Bowyer et al., 1998), we analyzed TH 
expression by immunohistochemistry and DAT expression by autoradiography in the 
Caudate Putamen (CPu) of PTN-Tg and WT mice treated with either amphetamine or 
saline (control). Two-way ANOVA revealed a significant effect of the genotype (F(1,21) = 
9.148; P = 0.0064), of the treatment (F(1,21) = 44.66; P < 0.0001) and a significant 
interaction between genotype and treatment (F(1,21) = 5.749; P < 0.0259) on striatal TH 
expression. Amphetamine caused a ~40 % depletion of TH contents in the CPu of WT mice 
compared with saline-treated WT mice (Fig. 1). We detected a significantly greater 
decrease of TH levels in the CPu of amphetamine-treated PTN-Tg mice compared to WT 
mice (Fig. 1). However, we did not find significant differences in the levels of TH in the 
striatum of saline-treated PTN-Tg and WT mice (Fig. 1).  
In order to discard the possibility that genotypic differences in amphetamine-
induced TH loss could be related to differences in this enzyme’s transcription and non-
necessarily to an enhanced loss of dopaminergic terminals, we tested DAT expression by 
autoradiography in the CPu (Fig. 2). As expected, amphetamine showed a significant 
impact in striatal DAT contents (F(1,20) = 28.54; P < 0.0001). Amphetamine tended to 
produce a greater decrease of DAT levels in the CPu of PTN-Tg mice (Fig. 2B). 
Considering the medial CPu, DAT levels were significantly reduced by amphetamine 
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treatment only in PTN-Tg mice (Fig. 2C), whereas reduction of DAT levels was not 
statistically different in the lateral CPu of both genotypes (Fig. 2D). 
3.2.  Enhanced amphetamine-induced increase of GFAP-positive astrocytes in the 
striatum of PTN-Tg mice. 
In these experiments, very few GFAP-positive astrocytes were observed in the 
striata of saline-treated mice (Fig. 3A). These cells were characterized by small cell bodies 
as well as very fine and short processes. In contrast, after amphetamine administrations, 
GFAP-positive astrocytes developed large cell bodies as well as long and extensive 
processes (Fig. 3A). In the case of amphetamine-treated PTN-Tg mice, astrocytes 
developed larger densely stained cell bodies as well as longer processes compared with WT 
mice (Fig. 3A). In addition, two-way ANOVA revealed a significant effect of the genotype 
(F(1,12) = 24.08; P = 0.0004), of the treatment (F(1,12) = 62.93; P < 0.0001) and a 
significant interaction between genotype and treatment (F(1,12) = 20.48; P < 0.001) on the 
number of GFAP+ cells/mm
2
 in the striatum. The number of GFAP+ cells in amphetamine-
treated mice increased in both genotypes when compared to the saline-treated groups (Fig. 
3B). However, a highly significant increase in the number of GFAP-positive astrocytes in 
the striata of PTN-Tg mice compared to WT mice was found (Fig. 3B). 
3.3.  D1, D2 binding in the brains of WT and PTN-Tg mice. 
No significant differences in D1, D2 receptors binding were observed in the CPu of 
PTN-Tg and WT mice (Figs. 4, 5). When medial and lateral CPu were analyzed separately, 
D1R and D2R binding was found to be similar in both genotypes (Figs. 4, 5). In addition, 
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no significant genotype or treatment effect was detected in D1 binding (table 1) and in D2 
binding (table 2) in any of the regions analyzed. 
3.4. Decreased amphetamine-induced conditioned place preference in PTN-Tg mice. 
To test the possibility that PTN could modulate amphetamine rewarding effects, we 
performed conditioning studies. We used a medium dose of amphetamine (3.0 g/kg, i.p.) 
known to induce CPP in this mouse strain (Gramage et al., 2010a; Tzschentke, 2007). Thus, 
as expected, amphetamine caused a robust CPP in WT mice (Fig. 6). However, 
amphetamine place preference score was decreased by 65 percent in PTN-Tg mice (Fig. 6, 
[t(22)=2.29, P=0.031]). As shown before with the same genotypes (Vicente-Rodriguez et al., 
2014a), saline conditioning did not show significant changes on place preference compared 
to preconditioning values of both genotypes (data not shown). The data confirm an 
important role of PTN in the regulation of the rewarding effects of amphetamine. 
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4. DISCUSSION 
In previous studies, it was shown that PTN-/- mice exhibit exacerbated 
amphetamine-induced dopaminergic damage in the nigrostriatal pathway (Gramage et al., 
2010a; 2010b). Thus, we hypothesized a possible neuroprotective role of PTN in response 
to the neurotoxic effects of amphetamine. However, one has to be cautious in making 
conclusions from knockout mice assays as data collected in these mice are subjected to the 
inherent limitations of a constitutive knockout animal model. To evaluate the potential 
neuroprotective role of PTN against amphetamine-induced neurotoxicity, we have now 
studied the effects of this drug in the striatum of mice with transgenic overexpression of 
PTN in the brain. In support of this rationale, studies with parkinsonian toxins had 
previously shown that overexpression of PTN exerts neuroprotection in mouse models of 
PD (Gombash et al., 2012; 2014). Unexpectedly, we found that amphetamine-induced loss 
of striatal TH and DAT contents is increased in PTN-Tg mice, suggesting that 
dopaminergic denervation caused by amphetamine is facilitated by PTN overexpression. 
This apparent discrepancy in the data collected from amphetamine-treated PTN-/- and 
PTN-Tg mice may reflect the possibility of compensatory mechanisms triggered by the 
elimination of PTN during development in the PTN knockout mice. These compensatory 
mechanisms are not clear but could be related to the signaling pathways regulated by PTN. 
PTN binds Receptor Protein Tyrosine Phosphatase (RPTP) β/ζ (also known as PTPRZ1) 
and inactivate its intrinsic tyrosine phosphatase activity
 
(Gramage and Herradon, 2011). As 
a result, PTN causes increases in the phosphorylation levels of substrates of RPTPβ/ζ 
known to be important for neuronal function (e.g. Fyn kinase and β-catenin) which, in turn, 
trigger other signaling pathways involved in different functions including mitogenic, 
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differentiation, survival and inflammation (Herradon and Perez-Garcia, 2014). Thus, it 
seems reasonable to hypothesize that some substrates of RPTPβ/ζ, or downstream factors in 
their signaling pathways, could be involved in compensatory developmental mechanisms in 
PTN-/- mice. 
The neuroprotective effects of PTN against cocaine- and amphetamine-induced 
toxicity have been proven in vitro. PTN (3 μM) limits amphetamine- and cocaine-induced 
decrease in PC12 and NG108-15 cell viability (Gramage et al., 2008; Gramage et al., 
2010a; 2010b). However, our results show that the net effect produced by PTN seems to 
differ in vivo, suggesting overall deleterious effects triggered by activation of PTN 
downstream pathways that could counteract its trophic actions on neurons. For instance, 
PTN induces the proliferation of immune cells and the expression of inflammatory 
cytokines including TNF-alpha, IL-1beta and IL-6 (Achour et al., 2001; 2008), suggesting a 
proinflammatory role of PTN. Previously, we showed a modest increase (~20%) of 
amphetamine-induced GFAP-positive astrocytes in PTN-/- mice (Gramage et al., 2010a). 
We now show a 13-fold upregulation of GFAP+ cells in the striatum of amphetamine-
treated PTN-Tg mice. Since merely a few astrocytes were sparsely detected throughout the 
striatum of control mice and it is known that GFAP labeling of striatal astrocytes can be 
sparse compared with other astrocyte markers in naïve animals (Kalman and Hajos, 1989; 
Krasnova et al., 2005; Tong et al., 2014), our data should not be interpreted as changes to 
astrocyte density without further confirmation. Most likely, our data reflect a highly 
significant amphetamine-induced upregulation of GFAP protein concentrations in 
astrocytes. Although a limitation of the present study is that microglial response has not 
been assessed, it has to be noted that overexpression of GFAP is an indicator of reactive 
astrogliosis and neuroinflammation, important events in a wide variety of CNS disorders 
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and pathologies (Sofroniew and Vinters, 2010). Thus, the robust increase of GFAP-positive 
astrocytes in amphetamine-treated PTN-Tg mice suggests an enhanced neuroinflammation 
induced by amphetamine in the presence of higher levels of PTN. Indeed these findings 
clearly indicate that PTN is involved in the neuroinflammatory promoting effect of 
amphetamine. A proposed model for this is illustrated in Fig. 7. It is important to note that 
different drugs of abuse, including amphetamine and its derivatives, induce 
neuroinflammation (Coelho-Santos et al., 2012) and that exacerbated neuroinflammatory 
responses, including astrocytosis, have been linked to neurodegenerative processes and 
CNS injury in different models (Qin et al., 2007; Sanchez-Guajardo et al., 2013). Our 
current findings, together with the fact that amphetamine administration increases the levels 
of expression of PTN in the brain (Le Greves, 2005), suggest the possibility that PTN may 
be one of the mediators facilitating amphetamine-induced neuroinflammation and, as a 
result, neurotoxicity (Fig. 7). 
The major cause of amphetamines neurotoxicity in the striatum is the dysregulation 
of dopamine and dopamine receptors (Ares-Santos et al., 2013). It has been shown that 
D1R antagonists protect against amphetamines-induced decreases in DAT binding in the 
striatum (Angulo et al., 2004) and inhibit the striatal denervation caused by these drugs (Xu 
et al., 2005). In a similar manner, inactivation of D2R prevents methamphetamine-induced 
reductions of striatal TH and DAT levels (Ares-Santos et al., 2013). Interestingly, the use of 
antagonists or genetic inactivation of D1R and D2R has been shown to reduce the enhanced 
striatal astrogliosis induced by amphetamines (Ares-Santos et al., 2013; Xu et al., 2005), 
suggesting that both receptors are also involved in the neuroinflammation caused by this 
type of drugs. However, our data demonstrate that D1R and D2R binding is not altered by 
amphetamine treatment and is similar in all the brain regions analyzed, including striatum, 
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of PTN-Tg and WT mice. The data clearly suggest that amphetamine-induced enhanced 
fibre loss and astrogliosis in the striatum of PTN-Tg mice is independent of D1R- and 
D2R-related mechanisms at least at the receptor expression level.  
Finally, we also tested the rewarding effects of amphetamine in PTN-Tg and WT 
mice. We previously found that amphetamine induces place preference in both PTN 
knockout and WT mice in a similar manner (Gramage et al., 2010a). However, extinction 
of amphetamine-induced CPP was delayed in PTN-/- mice suggesting a possible role of 
PTN in amphetamine reward. In the present work, our results uncover that overexpression 
of PTN significantly blocks amphetamine-induced conditioned place preference, suggesting 
an important role of PTN in the limitation of the rewarding effects of amphetamine. 
Interestingly, it was recently shown that alcohol-induced CPP was completely absent in 
PTN-Tg mice (Vicente-Rodriguez et al., 2014a). Overall, the data suggest a hyporeactive 
rewarding system of PTN-Tg mice in response to different drugs of abuse that is not related 
to deficits in D1, D2 receptors expression levels.  
In summary, the present study clarifies the role of PTN in amphetamine-induced 
neurotoxicity and reward. We demonstrate for the first time that brain overexpression of 
PTN blocks amphetamine-induced CPP. We also demonstrate that the net effect of brain 
overexpression of PTN is the enhancement of amphetamine-induced neurotoxic effects in 
the striatum despite previous evidences in PTN-/- mice pointing to an overall 
neuroprotective role of PTN in this context. In addition, the data demonstrate that increased 
amphetamine neurotoxicity in the striatum caused by overexpression of PTN is not related 
to changes in D1R and D2R expression. The data suggest that enhanced neuroinflammation 
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triggered by PTN overexpression could be involved in the greater striatal dopaminergic 
denervation caused by amphetamine in PTN-Tg mice.  
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FIGURE LEGENDS 
Fig. 1. TH expression in striatum of PTN-Tg and WT mice after amphetamine 
administration. TH-immunostained striatal sections of mice treated with saline (Sal) or 
amphetamine (Amph) (n=6-7/group). (A) Photomicrographs illustrate that PTN 
overexpression increases amphetamine-induced TH loss. (B) Graph represents the optical 
density (OD) measures of TH-ir in the striatum. ** p < 0.01 vs. Sal. *** p < 0.001 vs. Sal. # 
p < 0.05 vs. WT-Amph. Scale bar = 300 μm. 
Fig. 2. [
3
H]mazindol binding in WT and PTN-Tg mice treated with amphetamine. (A) 
Representative autoradiograms of [
3
H]mazindol binding to DAT in the brain sections of 
WT and PTN-Tg mice treated with saline (Sal) or amphetamine (Amph) (n=6/group). 
Representative autoradiograms of non-specific binding (NSB) was determined in the 
presence of 10 μM mazindol. The colour bar represents pseudo-color interpretation of black 
and white film images in fmol/mg tissue. (B) Quantitative autoradiography of [
3
H]mazindol 
binding in the brain of amphetamine- and saline-treated WT and PTN-Tg mice in CPu, (C) 
in CPuM and (D) in CPuL. ** p<0.01 vs. Sal. *** p<0.001 vs. Sal. Abbreviations: CPu, 
Caudate putamen; CPuL, Lateral part of CPu; CPuM, Medial part of CPu.  
Fig. 3. Amphetamine induces astrocytosis in the striatum of WT and PTN-Tg mice. 
(A) Photomicrographs are from GFAP-immunostained striatal sections of saline (Sal)- or 
amphetamine (Amph)-treated animals (n=4/group). Higher magnifications images in the 
lower right corner of every representative picture show that some of the astrocytes were 
hypertrophic and densely stained in WT mice treated with amphetamine whereas this effect 
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was generalized in PTN-Tg mice treated with amphetamine. (B) The graph represents 
quantification of data obtained from the counts of GFAP-positive cells in standardized 
areas of the striatum. *** P<0.001 vs. Sal. ### P<0.001 vs. WT-Amph. Scale bar 5x = 200 
μm, 40x = 50 μm. 
Fig. 4. [
3
H] SCH23390 binding in WT and PTN-Tg mice treated with amphetamine. 
(A) Representative autoradiograms of [
3
H] SCH23390 binding to D1 in the brain sections 
of WT and PTN-Tg mice treated with saline (Sal) or amphetamine (Amph) (n = 6/group). 
Representative autoradiograms of non-specific binding (NSB) was determined in adjacent 
sections in the presence of 10 μM cis-flupentixol. The colour bar represents pseudo-color 
interpretation of black and white film images in fmol/mg tissue. (B) Quantitative 
autoradiography of [
3
H] SCH23390 binding in the brain of amphetamine- and saline-treated 
WT and PTN-Tg mice in CPu, (C) in CPuL and (D) in CPuM. Abbreviations: CPu, 
Caudate putamen; CPuL, Lateral part of CPu; CPuM, Medial part of CPu.  
Fig. 5. [
3
H]raclopride binding in WT and PTN-Tg mice treated with amphetamine. 
(A) Representative autoradiograms of [
3
H]raclopride binding to D2 in the brain sections of 
WT and PTN-Tg mice treated with saline (Sal) or amphetamine (Amph) (n = 6/group). 
Representative autoradiograms of non-specific binding (NSB) was determined in adjacent 
sections in the presence of 10 μM sulpiride. The colour bar represents pseudo-color 
interpretation of black and white film images in fmol/mg tissue. (B) Quantitative 
autoradiography of [
3
H]raclopride binding in the brain of amphetamine- and saline-treated 
WT and PTN-Tg mice in CPu, (C) in CPuL and (D) in CPuM. Abbreviations: CPu, 
Caudate putamen; CPuL, Lateral part of CPu; CPuM, Medial part of CPu.  
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Fig. 6. Amphetamine-induced conditioned place preference in PTN-Tg and WT mice. 
Preference score after amphetamine (3.0 mg/kg) conditioning, showing a significantly 
decreased amphetamine CPP in PTN-Tg mice. *P < 0.05 vs. WT. 
Fig. 7. Schematic model of the effects of amphetamine in genetically engineered PTN 
mouse models. In normal WT mice, amphetamine (Amph) induces striatal denervation and 
an increase in the expression levels of PTN. PTN exerts neurotrophic actions on striatal 
dopaminergic terminals but also contribute to astrogliosis and cytokine release causing 
deleterious effects in the striatum. PTN-/- mice show an increased striatal denervation and a 
modest increase of astrogliosis, possibly caused by compensatory mechanisms triggered by 
factors downstream of PTN signaling pathways. PTN-Tg mice show an exacerbated striatal 
dopaminergic denervation after amphetamine treatment, together with a highly significant 
(4-fold) increase of astrogliosis which will overtake the possibly augmented neurotrophic 
effects caused by overexpression of PTN and will aggravate striatal dopaminergic injury. 
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Table 1. Quantitative autoradiography of [
3
H]SCH23390 binding to D1 in brain sections of WT and PTN-Tg treated with 
amphetamine (Amph) or saline (Sal) (n = 6/group). 
 
[
3
H]SCH23390-specific binding (fmol/mg tissue) 
 
Sal 
 
Amph 
Region WT PTN-Tg 
 
WT PTN-Tg 
Nucleus accumbens core 360.8 ± 40.3 369.2 ± 39.2 
 
367.5 ± 43.7 362.8 ± 44 
Nucleus accumbens shell 332 ± 44.1 346.8 ± 42.7 
 
349.1 ± 37.4 339.7 ± 40 
Olfatory tubercle 290 ± 26.4 285.9 ± 24.2 
 
288.4 ± 31 299.4 ± 34.8 
Clastrum 112.2 ± 19.3 99.8 ± 15 
 
101.7 ± 15.3 95.4 ± 14.6 
Cingulate cortex 26.9 ± 2.9 25.2 ± 2 
 
 24.8 ± 6.7 29 ± 4.4  
Motor cortex 17.5 ± 2.5 19.4 ± 2.5 
 
20 ± 3.9 20.8 ± 3.1 
Amygdala 46.2 ± 6.9  49.6 ± 7.5 
 
52.7 ± 6.7 47.2 ± 7.2 
Thalamus 18.4 ± 2.9 24.3 ± 5.1 
 
26.9 ± 5.6 26.1 ± 6.9 
Hypothalamus 14.6 ± 3.5 21.5 ± 4.2 
 
18.6 ± 3.3 21 ± 3.6 
Hippocampus 26.2 ± 4 26.3 ± 6.6 
 
38.5 ± 6.4 28.1 ± 6.1 
Substantia nigra 184 ± 18.3 191.8 ± 10.8 
 
204.1 ± 13.6 181 ± 10.2 
Ventral tegmental area 21.3 ± 3.4 13.6 ± 2.9   18.6 ± 5.2 25.8 ± 8.2 
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[
3
H]raclopride-specific binding (fmol/mg tissue) 
 
Sal 
 
Amph 
Region WT PTN-Tg 
 
WT PTN-Tg 
Nucleus accumbens core 67.5 ± 11.8 54.2 ± 2.1 
 
67.63 ± 11.8 60.6 ± 11.1 
Nucleus accumbens shell 71.5 ± 12.5 70 ± 11.4 
 
64.8 ± 11.4 69.3 ± 12.6 
Olfatory tubercle 86.8 ± 16.5 76.6 ± 14.6   81.1 ± 15.6 82 ± 21.2 
Table 2. Quantitative autoradiography of [
3
H]raclopride binding to D2 in brain sections of WT and PTN-Tg treated with amphetamine 
(Amph) or saline (Sal) (n = 6/group). 
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